Primary operational goal for 2025 is to enter into multiple licensing agreements for human diagnostic applications, e.g. cancer & sepsis. In September, two (2) licensing agreements were signed: one with Werfen S.A. for Nu.Q NETs research and the other with Hologic for Nu.Q Discover services. Within the Nu.Q NETs pillar, the commercial strategy to utilize the CE Mark has brought on 11 hospital networks in Europe thus far in 2025. The hospitals are ordering and re-ordering Nu.Q products for human application.
